SOLARAZE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Solaraze, and when can generic versions of Solaraze launch?

Solaraze is a drug marketed by Fougera Pharms and is included in one NDA.

The generic ingredient in SOLARAZE is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-nine suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Solaraze

A generic version of SOLARAZE was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26^th, 1996.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SOLARAZE?
What are the global sales for SOLARAZE?
What is Average Wholesale Price for SOLARAZE?

Summary for SOLARAZE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	121
Clinical Trials:	11
Patent Applications:	3,921
What excipients (inactive ingredients) are in SOLARAZE?	SOLARAZE excipients list
DailyMed Link:	SOLARAZE at DailyMed

Drug patent expirations by year for SOLARAZE

Recent Clinical Trials for SOLARAZE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gesellschaft für Therapieforschung mbH	Phase 3
Infectopharm Arzneimittel GmbH	Phase 3
Novum Pharmaceutical Research Services	Phase 3

See all SOLARAZE clinical trials

Paragraph IV (Patent) Challenges for SOLARAZE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SOLARAZE	Topical Gel	diclofenac sodium	3%	021005	1	2009-12-16

US Patents and Regulatory Information for SOLARAZE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SOLARAZE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	⤷ Sign Up	⤷ Sign Up
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	⤷ Sign Up	⤷ Sign Up
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	⤷ Sign Up	⤷ Sign Up
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	⤷ Sign Up	⤷ Sign Up
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	⤷ Sign Up	⤷ Sign Up
Fougera Pharms	SOLARAZE	diclofenac sodium	GEL;TOPICAL	021005-001	Oct 16, 2000	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SOLARAZE

See the table below for patents covering SOLARAZE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Hungary	9303283		⤷ Sign Up
Japan	3811500		⤷ Sign Up
New Zealand	249071	TOPICAL MEDICAMENTS CONTAINING A HYALURONIC ACID OR SALT OR DERIVATIVE TO ENHANCE PENETRATION OF DRUG INTO THE SKIN	⤷ Sign Up
Portugal	626864		⤷ Sign Up
Slovakia	137996	CANCER TREATMENT AND METASTASIS PREVENTION	⤷ Sign Up
African Regional IP Organization (ARIPO)	9500756		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for SOLARAZE

Recent Clinical Trials for SOLARAZE

Paragraph IV (Patent) Challenges for SOLARAZE

Make Better Decisions: Try a trial or see plans & pricing